Tatiana Shelekhova

TL;DR: Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies has synergistic anti-myeloma activity when combined with bortezomib and dexamethasone and the proportion of patients achieving an overall response did not differ between treatment groups.

TL;DR: Among patients with newly diagnosed multiple myeloma who were ineligible for stem‐cell transplantation, daratumumab combined with bortezomib, melphalan, and prednisone resulted in a lower risk of disease progression or death than the same regimen without darumumab.

TL;DR: The primary endpoint was progression-free survival, which has been reported previously, and remained significantly improved for the D-VMP group, and results presented are from a prespecified interim analysis for overall survival.

TL;DR: This trial investigated the activity and safety of three different dosing regimens of oral panobinostat in combination with subcutaneous bortezomib and oral dexamethasone for patients with relapsed or relapsed and refractory multiple myeloma.

TL;DR: Significant clinical activity, including complete responses, was observed in a phase Ib study of panobinostat + bortezomib in patients with relapsed or relapsed and refractory MM, and pooled safety data (blinded) was observed.